Kiromic BioPharma has announced that the University of Arizona Cancer Center has been activated as the fifth clinical trial site for their Phase 1 Deltacel-01 trial. This trial aims to evaluate the safety and efficacy of Kiromic’s cell therapy product in patients with advanced solid tumors.
The University of Arizona Cancer Center is a renowned institution known for its cutting-edge research and treatment of cancer. By activating them as a clinical trial site, Kiromic BioPharma is expanding their reach and giving more patients access to potentially life-saving treatments.
The Deltacel-01 trial is an important step in Kiromic’s mission to develop innovative therapies for cancer. The company’s cell therapy product is designed to target and destroy cancer cells while leaving healthy cells unharmed, offering a more targeted and less toxic approach to treatment.
With the activation of the University of Arizona Cancer Center as a clinical trial site, Kiromic BioPharma is advancing their research efforts and bringing hope to patients with advanced solid tumors. This collaboration also highlights the importance of partnerships between industry and academia in driving medical advancements and improving patient outcomes.
Overall, the activation of the University of Arizona Cancer Center as a clinical trial site for the Phase 1 Deltacel-01 trial is a significant milestone for Kiromic BioPharma. It demonstrates their commitment to advancing cancer research and bringing novel therapies to patients in need.
Source
Photo credit news.google.com